Jacobs Levy Equity Management, Inc Exelixis, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 2,082,283 shares of EXEL stock, worth $73.4 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

2,082,283

Previous 2,521,183 17.41%

Holding current value

$73.4 Million

Previous $56.7 Million 4.62%

% of portfolio

0.22%

Previous 0.24%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $9.64 Million - $12.1 Million	-438,900 Reduced 17.41%	2,082,283 $54 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $2.34 Million - $2.73 Million	115,234 Added 4.79%	2,521,183 $56.7 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $827,696 - $981,991	41,036 Added 1.74%	2,405,949 $57.1 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $18 Million - $22.6 Million	-935,281 Reduced 28.34%	2,364,913 $56.7 Million
Q3 2023 Nov 16, 2023	SELL	$19.04 - $22.74 $1.48 Million - $1.76 Million	-77,558 Reduced 2.3%	3,300,194 $72.1 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $567,885 - $640,081	-31,254 Reduced 0.92%	3,377,752 $64.5 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $3.45 Million - $4.1 Million	211,416 Added 6.61%	3,409,006 $66.2 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $9.45 Million - $11 Million	631,552 Added 24.61%	3,197,590 $51.3 Million
Q3 2022 Nov 15, 2022	BUY	$15.68 - $22.27 $3.86 Million - $5.49 Million	246,479 Added 10.63%	2,566,038 $40.2 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $1.39 Million - $1.84 Million	-79,552 Reduced 3.32%	2,319,559 $48.3 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $2.65 Million - $3.53 Million	155,587 Added 6.93%	2,399,111 $54.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $16.1 Million - $22.3 Million	1,018,237 Added 83.1%	2,243,524 $41 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $18.2 Million - $23.6 Million	1,116,242 Added 1023.65%	1,225,287 $25.9 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $1.96 Million - $2.79 Million	109,045 New	109,045 $1.99 Million
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $781,844 - $987,676	-39,890 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $2,730 - $4,360	-200 Reduced 0.5%	39,890 $785,000
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $87,126 - $122,975	-5,490 Reduced 12.04%	40,090 $710,000
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $394,771 - $477,511	-21,270 Reduced 31.82%	45,580 $981,000
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $398,035 - $573,063	17,970 Added 36.76%	66,850 $1.48 Million
Q4 2017 Feb 13, 2018	BUY	$24.23 - $30.93 $370,719 - $473,229	15,300 Added 45.56%	48,880 $1.49 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $109,044 - $136,550	4,670 Added 16.15%	33,580 $814,000
Q2 2017 Nov 09, 2017	BUY	N/A	28,910	28,910 $712,000

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Exelixis, Inc. Transaction History